X

Trial Profile

Phase 1 Study of Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE) in Combination With TAS-102 (LONSURF) in Refractory Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 22 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Irinotecan (Primary) ; Tipiracil/trifluridine (Primary)
Indications Cholangiocarcinoma; Neuroendocrine tumours; Solid tumours
Focus Adverse reactions
Sponsors PharmaEngine

Most Recent Events

15 Nov 2023 Status changed from active, no longer recruiting to completed.
17 Jul 2023 Planned End Date changed from 31 Dec 2022 to 31 Aug 2023.
22 Jan 2022 Results presented at the 2022 Gastrointestinal Cancers Symposium

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com